经济观察网特宝生物近期公告显示，公司拟发行可转换公司债券募集资金总额不超过15.33亿元，用于 新药研发等项目。同时，公司2025年业绩快报显示营业收入36.96亿元，同比增长31.18%，归母净利润 10.38亿元，同比增长25.39%。 定增股票 业绩经营情况 公司于2026年2月10日晚间披露了2025年业绩快报，显示营业收入36.96亿元，同比增长31.18%，归母净 利润10.38亿元，同比增长25.39%。业绩增长主要受重点产品派格宾销售收入稳定增长及新产品益佩生 上市推动。 以上内容基于公开资料整理，不构成投资建议。 特宝生物于2026年1月26日晚间公告，拟发行可转换公司债券募集资金总额不超过15.33亿元，用于新药 研发项目、生物技术创新融合中心建设项目及创新药物生产改扩项目。这一计划旨在加码主业，提升研 发能力和产能。 ...

长效生物制剂龙头特宝生物(688278.SH)经营业绩再现稳健增长。 2月10日晚，特宝生物披露了2025年业绩快报。当年，公司实现的营业收入、归母净利润分别为36.96亿 元、10.38亿元，同比增速均超过20%，均创下历史新高。 特宝生物解释，公司重点产品销售收入稳定增长，新产品获批上市带来销售收入新增长点。 长江商报记者发现，2018年至2025年的八个年度，特宝生物的营收净利实现了连续八年增长。 与业绩增长相关联的是，特宝生物的经营现金流持续净流入。2025年前三季度，公司经营现金流净额为 4.71亿元，同比增长61.33%。 特宝生物重点聚焦乙肝临床治愈领域，截至2025年6月末，公司已经上市六个药品及一款电子笔式注射 器。 特宝生物的研发投入持续增加，2025年前三季度，公司研发投入为3.12亿元，同比增长38.67%。 特宝生物持续回报股东。2020年上市以来，公司已经连续五年分红，合计分红5.67亿元，为股权融资额 的1.5倍。 年度盈利首次突破10亿大关 特宝生物业绩延续双增的良好发展势头。 根据最新发布的业绩快报，2025年，特宝生物实现营业收入36.96亿元，同比增长31.18%；归母净 ...

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where all proposed resolutions were approved without any objections from shareholders [2][9]. Group 1: Meeting Details - The meeting took place on February 11, 2026, at the company's conference room located at 330 Wengjiao Road, Haicang New Industrial Zone, Xiamen [2]. - The meeting was convened by the board of directors and chaired by Mr. Sun Li, the chairman [2]. - The voting method combined on-site and online voting, complying with the Company Law and the company's articles of association [2]. Group 2: Attendance - All 9 current directors attended the meeting, along with the company secretary Ms. Yang Yiling and some senior management personnel [3]. Group 3: Resolutions Reviewed - The following resolutions were passed: - Approval for the company to issue convertible bonds to unspecified investors [4]. - Approval of the bond issuance plan, including types of securities, issuance scale, face value, issuance price, bond term, interest rate, repayment terms, conversion period, and pricing adjustments [4][5][6][7]. - Approval of the use of raised funds, management of funds, and related guarantees [7]. - Approval of the feasibility analysis report for the use of raised funds and the dilution of immediate returns with measures to compensate [8]. - Approval of the company's dividend return plan for the next three years (2026-2028) [8]. - Authorization for the board of directors to handle all matters related to the issuance of convertible bonds [8]. Group 4: Voting and Legal Verification - All resolutions were special resolutions and were passed with more than two-thirds of the voting rights held by attending shareholders [9]. - The meeting was witnessed by lawyers from Shanghai Jintiancheng (Shenzhen) Law Firm, who confirmed that the meeting complied with legal and procedural requirements [9].

证券代码：688278 证券简称：特宝生物 公告编号：2026-012 （一） 股东会召开的时间：2026 年 2 月 11 日 （二） 股东会召开的地点：厦门市海沧新阳工业区翁角路 330 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 普通股股东人数 | 107 | | 2、出席会议的股东所持有的表决权数量 | 229,173,676 | | 普通股股东所持有表决权数量 | 229,173,676 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 56.14 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.14 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 厦门特宝生物工程股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 ...

上海市锦天城（深圳）律师事务所 关于 厦门特宝生物工程股份有限公司 2026 年第一次临时股东会之 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于厦门特宝生物工程股份有限公司 2026 年第一次临时股东会之 法律意见书 致：厦门特宝生物工程股份有限公司 根据厦门特宝生物工程股份有限公司（以下简称"贵公司"或者"公司"）的委托，并 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）等法律、行政法规以及《厦门特宝生物工程股份有限公司章程》 （以下简称"《公司章程》"）、《厦门特宝生物工程股份有限公司股东会议事规则》（以 下简称"《股东会议事规则》"）的规定，上海市锦天城（深圳）律师事务所（以下简称"本 所"）指派律师见证公司 2026 年第一次临时股东会（以下简称"本次股东会"），现就公 司本次股东会召开的有关事宜出具本法律意见书。 本所同意将本法律意见书随贵公司本次股东会的 ...

Core Viewpoint - The company reported significant growth in both revenue and net profit for the year 2025, driven by stable sales of key products and the introduction of new products [1] Financial Performance - The company achieved an annual revenue of 3.696 billion yuan, representing a year-on-year increase of 31.18% [1] - The net profit attributable to shareholders reached 1.038 billion yuan, reflecting a year-on-year growth of 25.39% [1] Key Growth Drivers - The substantial revenue growth is primarily attributed to the stable sales of the key product, Paigebin [1] - The approval and market launch of the new product, Yipeisheng, provided a new revenue growth point for the company [1]

健业家首发｜2月10日，厦门特宝生物工程股份有限公司（证券代码：688278，证券简称：特宝生物）发布2025年度业绩快报公告，全年业绩稳步增长。 或受业绩影响，2月11日，公司股价高开高走，收涨6.01%，市值297.98亿元。 业绩快报显示，2025年度特宝生物实现营业总收入36.96亿元（上年同期28.17亿元），同比增长31.18%；营业利润12.54亿元（上年同期9.71亿元），同比 增长29.14%；利润总额11.78亿元（上年同期9.31亿元），同比增长26.56%。归属于母公司所有者的净利润10.38亿元（上年同期8.28亿元），同比增长 25.39%；归属于母公司所有者的扣除非经常性损益的净利润10.67亿元（上年同期8.27亿元），同比增长29.09%，盈利水平稳步提升。 每股收益方面，公司2025年基本每股收益2.55元（上年同期2.03元），同比增长25.62%；加权平均净资产收益率35%（上年同期37.69%），同比减少2.69 个百分点。 对于公司核心产品及管线布局，研报认为，派格宾收入自2016年0.7亿元增长至2024年24.5亿元，持续放量；益佩生作为治疗用生物制品国家Ⅰ类新 ...

（特宝生物公告） 报告期内，公司整体经营及财务状况稳健，主要得益于重点产品派格宾销售收入的稳定增长以及新产品 益佩生的上市带来的新销售增长点。尽管新产品上市初期市场拓展及核心产品覆盖提升导致相关费用增 加，但公司创新成果的快速临床应用推动了整体经营的稳健增长。 近日，特宝生物发布公告称，2025年度公司实现营业总收入36.96亿元，同比增长31.18%；归母净利润 为10.38亿元，同比增长25.39%。 ...

Core Insights - The news highlights significant corporate announcements and performance reports from various companies, indicating potential investment opportunities and market movements. Group 1: Corporate Announcements - Ge Weidong invested 1 billion yuan to subscribe for shares in Jianghuai Automobile's private placement, acquiring approximately 20.05 million shares at a price of 49.88 yuan per share, contributing to a total fundraising of about 3.5 billion yuan from eight investors [3][4] - *ST Cube completed its suspension review and will resume trading on February 11, 2026, after confirming no undisclosed significant matters related to the company [2] - Yunnan Baiyao plans to invest 137 million yuan in a second phase project for oral liquid production to meet growing market demand [11] Group 2: Performance Reports - Semiconductor manufacturer SMIC reported a 23.2% year-on-year increase in net profit for Q4 2025, reaching 1.223 billion yuan, driven by increased wafer sales and improved capacity utilization [5] - Special Biological Company reported a net profit of 1.038 billion yuan for 2025, reflecting a 25.39% increase year-on-year, attributed to stable sales of key products and new product approvals [6] - New Zobang achieved a net profit of 1.098 billion yuan in 2025, marking a 16.56% increase compared to the previous year [6] Group 3: Fundraising and Restructuring - New Han New Materials plans to raise up to 1 billion yuan through a private placement to fund projects related to high-performance resins and composite materials [8] - Chutian Long intends to raise up to 760 million yuan for the development of innovative safety products and digital operations [8] - Yi Yi Co. decided to terminate its plan to acquire 100% equity of a pet food company due to changes in the target company's operational conditions [8] Group 4: Major Contracts and Investments - Yunjiji Group signed an EPC contract worth 1.331 billion yuan for a cement production line and power station in Zimbabwe, representing 86.66% of the company's audited revenue for 2024 [9] - Solar Energy's subsidiary plans to acquire 100% of Jinhua Windling for 527 million yuan, enhancing its position in the solar power industry [9] - Yutong Technology intends to acquire 51% of Huayan Technology for 448.8 million yuan, which will become a subsidiary post-transaction [9]

Mergers and Acquisitions - Yiyi Co. has terminated the acquisition of 100% equity in Hangzhou Gaoye Family due to failure to reach an agreement on valuation with the counterparties, influenced by the company's adjustments in sales models and new product promotions for the 2025 Double Eleven event [1] - Solar Energy's wholly-owned subsidiary, China Energy Conservation Solar Technology Co., plans to acquire 100% equity in Jinhua Windling New Energy Development Co. for 527 million yuan, with the target company's audited book value at 545 million yuan as of August 31, 2025. This transaction does not constitute a major asset reorganization [2] Performance Disclosure - SMIC reported a net profit of 5.041 billion yuan for 2025, reflecting a year-on-year growth of 36.3%, with operating revenue of 67.323 billion yuan, up 16.5% [3] - Tebao Bio announced a total operating revenue of 3.696 billion yuan for 2025, marking a year-on-year increase of 31.18%, and a net profit attributable to the parent company of 1.038 billion yuan, up 25.39% [4] - Guoke Tiancai reported an operating revenue of 1.102 billion yuan for 2025, a year-on-year growth of 14.73%, with a net profit of 204 million yuan, increasing by 17.94% [5] Shareholding Changes - Haitai Technology's controlling shareholder, Sun Wenqiang, plans to reduce his stake by up to 3.00%, amounting to a maximum of 2.9845 million shares due to personal financial needs [6] - Rike Chemical's shareholder, Zhao Dongri, intends to reduce his holdings by no more than 3%, equating to a maximum of 1.3498 million shares [7] - Magu Technology's shareholder, Baolifeng, along with its concerted actor Dong Jiyong, plans to reduce their holdings by up to 3%, totaling a maximum of 2.1496 million shares [8]